The lipogenic phenotype is a metabolic hallmark of cancer cells. Sterol regulatory Research.
Introduction
Altered metabolism is a hallmark of cancer cells (1) (2) (3) . Cancer cells show increases in glucose uptake and glycolysis. The metabolic changes play an important role in their malignant properties. Cancer cells also display the lipogenic phenotype (4) Lipid synthesis is tightly controlled by transcriptional regulation of lipogenic enzymes. Sterol regulatory element binding proteins (SREBPs) -1 and -2 are master transcriptional factors that regulate cholesterol and fatty acid biosynthesis (7) . SREBPs are localized in endoplasmic reticulum (ER) membrane as a precursor and form a complex with SREBP-cleavage activating protein (Scap) and Insig (8) . Upon a decrease in cellular sterol level, Insig dissociates from the complex and SREBP/Scap is transported to the Golgi apparatus where the precursors are cleaved to release the mature forms. The mature forms then enter into the nucleus and transactivate target genes. SREBP-1 and -2 regulate both cholesterol and fatty acid biosyntheses (9) . Sterols are well-known regulators of SREBPs, whereas recent studies have shown that SREBP is also regulated by phosphatidylinositol 3-kinase (PI3K)-Akt signaling (10) which is often hyperactivated in carcinomas. SREBP mature forms are increased in human cancers (11, 12) . Roles of cancer-associated molecules in the regulation of SREBP, however, are largely unknown. Changes in carbohydrate moieties of certain proteins and glycosphingolipids (GSLs) have frequently been observed in carcinomas. GSLs modulate cell signaling through growth factor receptors and/or integrins (13) . In melanomas, one of the most aggressive cancers, disialylganglioside GD3 is widely expressed as a melanoma antigen (14, 15) . GD3 expression has also been reported in other cancers (16) (17) (18) . We and others showed that GD3 enhances proliferation and invasive activity of melanoma and other cells (19) (20) (21) (22) although the molecular mechanism remains poorly understood. GD3 mediates such functions in membrane microdomains known as lipid rafts where cholesterol and sphingolipids are enriched (23) .
Lipid rafts are essential for various cellular functions (24) . How the microdomains are properly maintained on cellular demands is not well understood.
In this study, we examined a role of the melanoma antigen GD3 in the lipogenic phenotype in human melanoma cells. Signaling pathway regulating the lipogenic pathway and a role of the lipogenic phenotype in their malignant properties were also investigated. Based on the current results, we propose a positive feedback regulatory loop in which the activation of SREBP pathway by PI3K-Akt-mammalian target of rapamycin complex 1 (mTORC1) signaling is crucial for the reinforcement of Akt signaling. Lyoyd and J. Nakano, Year 2002) were isolated from SK-MEL-28 as a GD3-deficient clone (25) . N1 cell clones expressing GD3 synthase (G5 and G11) and a mock transfectant (V9)
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Research. (150 mCi/mmol, American Radiolabeled Chemicals) into cholesterol and phosphatidylcholine (PC) as described (26) . Amounts of cholesterol and choline-phospholipids were determined by colorimetric enzymatic assay systems (Kyowa Medex) as described (27) .
Immunofluorescence staining. Cells grown on poly-L-lysine coated glass coverslips were treated as described in the Figure Legend. Cells were fixed with 2% paraformaldehyde for 10 min and permeabilized with 0.1% Triton X-100 for 5 min. After specimens were blocked with 4% FBS for 1 h, they were incubated with anti-p-Akt (Ser473) and anti-GD3 antibodies (15 (Fig. S1 ). We thus asked whether GD3 expression induces lipogenic pathway. We employed N1 cell clones with or without GD3 expression (Fig. S1 ). GD3-positive G5 and G11 cells showed increases in both SREBP-1 and SREBP-2 mature forms compared to parental N1 and control V9 cells ( Fig.   2A ). Both G5 and G11 cells also expressed higher levels of HMGR. Accordingly, cholesterol biosynthesis was substantially increased in G5 and G11 cells (Fig. 2B) . However, FAS expression ( Fig. 2A ) and PC biosynthesis (Fig. 2C) were not affected by GD3 expression.
Human melanoma cells often express oncogenic BRAF V600E (28) , which constitutively activates ERK signaling. Levels of SREBP mature forms ( Fig. 1) were not correlated to BRAF genotypes previously identified (28, 29) . It thus seems unlikely that the SREBP pathway is regulated by a PI3K-Akt-mTORC1 signaling. We previously showed that GD3 enhances cellular signalings including Akt (19, 20) . We thus asked whether GD3-induced signalings are involved in SREBP regulation in human melanoma cells. As reported (10), the specific PI3K inhibitor LY294002 reduced mature forms of SREBP-1 and SREBP-2 in SK-MEL-28 ( Fig. 3A ) and G11 cells (data not shown).
Wortmannin, another PI3K inhibitor also produced similar results (data not shown). The mTORC1 kinase is regulated downstream of Akt. Whether mTORC1 is involved in the regulation of SREBP activity has been open to debate (10) . Furthermore, its involvement in SREBP-2 processing has remained unknown. The mTORC1 specific inhibitor rapamycin reduced mature forms of both SREBPs with higher sensitivity toward SREBP-1 (Fig. 3A) .
These results suggest that mTORC1 is involved in the regulation of SREBPs in melanoma cells. However, prolonged treatment with or treatment at high concentration of rapamycin are known to inhibit mTORC2, which phosphorylates Akt at serine 473 (30) . To validate the involvement of mTOR complexes in SREBP processing, the mTORC1 component Raptor, the mTORC2 component Rictor, or both of them were silenced by specific siRNAs, and SREBP cleavage was examined. Silencing Raptor and/or Rictor markedly reduced both SREBP-1 and SREBP-2 mature forms ( Fig. 3B ), indicating that both mTORC1 and mTORC2 play a role in the SREBP processing. Insig-1 expression was affected neither by Raptor nor Rictor knockdown.
Amounts of SREBP mature forms are regulated by two independent mechanisms (7); the two-step proteolytic cleavage and proteasomal degradation ( were treated with or without LY294002 and/or MG132, a proteasomal inhibitor. LY294002 reduced mature forms of SREBP-1 and SREBP-2 within 2 h, whereas MG132 rapidly increased the mature forms (Fig. 3D) . When the cells were treated with both compounds, increases in mature forms of both SREBPs were suppressed, suggesting that PI3K-Akt signaling is involved in the processing step in melanoma cells.
To further explore signaling cascade that regulates SREBP processing, SK-MEL-28 cells were stimulated with insulin-like growth factor-1 (IGF-1), which activates Akt signaling and is an important growth factor for malignant properties of melanoma cells (31) . IGF-1 increased mature forms of SREBPs and HMGR expression within 2 h ( and absence of IGF-1, but cholesterol biosynthesis was more sensitive to the compound.
Effect of SREBP inactivation on lipid raft-associated signaling. Cholesterol is essential for the formation of lipid rafts. We explored whether PI3K-Akt-mTORC1-SREBP axis regulates the integrity of lipid rafts. The results showed that disruption of PI3K-Akt-mTORC1 signaling significantly reduces cholesterol contents in lipid rafts (Fig.   S2 ), which impairs the balance of cholesterol distribution between lipid rafts and non-lipid rafts (Fig. 4D) . Changes in phospholipid distribution by these inhibitors were only modest.
Lipid rafts play an important role in Akt signaling (32) (33) (34) (35) (36) . We next examined a role of SREBPs in Akt activation. 25-hydroxycholesterol (25HC) inhibits SREBP processing by sequestering the SREBP/Scap complex in the ER. It reduced both SREBP mature forms in SK-MEL-28 cells (Fig. S3) . SK-MEL-28 cells pretreated with or without 25HC were stimulated with IGF-1, and Akt phosphorylation was assessed. In the cells treated with 25HC, phosphorylation of Akt by IGF-1 was suppressed (Fig. 5A) . Inhibition of cholesterol biosynthesis also resulted in decreases in Akt phophorylation (Fig. S4) . SK-MEL-28 cells with or without the 25HC pretreatment were subjected to subcellular fractionation, and distribution of p-Akt was examined. The PM protein Na + /K + ATPase was enriched in the PM-rich fraction, but undetectable in the cytosol fraction. In contrast, the cytosolic protein FAS was detected only in the cytosol fraction (Fig. 5A) . Akt phosphorylation by IGF-1 was strongly suppressed in the PM-rich fraction prepared from the 25HC-treated cells. The 25HC treatment also slightly reduced cytosolic p-Akt. To further examine subcellular localization of p-Akt, we prepared lipid rafts. Majority of the lipid raft marker flotillin-1 was recovered in fraction 2 (Fig. 5B) . When the cells were stimulated with IGF-1, significant amounts of p-Akt were found in lipid raft fractions. In contrast, the level of p-Akt in lipid rafts was much lower
Research. in the IGF-1-stimulated cells pretreated with 25HC. To confirm these results, SK-MEL-28 cells pretreated with 25HC or vehicle were stimulated by IGF-1, and cellular localization of p-Akt and GD3 was examined under a confocal microscopy. IGF-1 treatment increased p-Akt signals at cell peripheries, which was suppressed by pretreatment of the cells with LY294002 (Fig. 5C ). p-Akt well colocalized with GD3, indicating that Akt is activated at or near GD3-enriched membrane microdomains. In contrast, p-Akt signals were not significantly increased upon IGF-1 stimulation in the cells pretreated with 25HC. 25HC seemed not to affect GD3 expression and distribution.
Roles of SREBP pathway in melanoma cell proliferation and tumorigenesis.
The effect of SREBP or cholesterol biosynthesis inhibitors on melanoma cell proliferation was assessed. 25HC, NB598 (a squalene monooxygenase inhibitor), and compactin (a HMGR inhibitor) all inhibited melanoma cell proliferation in the presence of FBS (Fig. 6A) . In addition, all these three compounds potentiated the inhibitory effect of LY294002 and rapamycin on their proliferation (Fig. 6B) . These results indicate that melanoma cells require high levels of SREBP-dependent cholesterol biosynthesis to maintain their rapid proliferation (Fig. 6C) .
Finally, we examined whether SREBP pathway plays a role in tumor growth in vivo.
We injected SK-MEL-28 cells into nude mice and treated the tumors with compactin or 25HC.
The treatment with compactin or 25HC significantly suppressed the growth of melanoma cells in a xenograft model (Fig. 7A and B) . These results clearly demonstrate a crucial role of SREBP pathway in tumorigenesis in vivo.
Discussion
Research. Almost all human melanomas express GD3 (14, 15) . We reported that GD3 expression in the GD3-negative mutants reinforces malignant properties of human melanoma cells (19, 20) . In this work, we investigated whether GD3 is involved in the lipogenic phenotype, a metabolic change often observed in cancer cells, and how the lipogenic pathway is regulated in human melanoma cells. The current study was also designed to address how the lipogenic phenotype augments malignant properties of melanomas.
We found that the SREBP pathway was activated in most of human melanoma cells.
The activation did not correlate with BRAF status, suggesting that ERK signaling is not involved in the induction of the lipogenic pathway. On the other hand, the forced expression of GD3 induced the processing of SREBPs, HMGR expression, and cholesterol biosynthesis. constitutive active form of epidermal growth factor receptor (EGFR), EGFRviii, causes hyperactivation of Akt and leads to SREBP-1 activation in an Akt-dependent manner (11) . In human melanoma, GD3 enhances Akt activation (19, 20) . We showed that GD3 expression promotes SREBP-1 and SREBP-2 processing through PI3K-Akt signaling. An important role of Akt was further confirmed by the finding that mTORC2 inhibition by silencing Rictor reduces SREBP processing. Our results also indicated that PI3K-Akt signaling regulates a step involved in the generation of the mature forms, which is consistent with a previous report (41) . Our current results together with previous studies thus elucidated that PI3K-mTORC2-Akt signaling regulates the processing of both SREBPs.
Whether mTORC1 is involved in the regulation of SREBP processing is an important issue to be clarified. In patients with gliobastoma, levels of SREBP-1 mature form in the tumor tissues were not affected by rapamycin treatment (11) . Rapamycin also failed to prevent SREBP-1 processing in glioblastoma cells expressing EGFRviii (11) . These results suggested that mTORC1 is not involved in SREBP-1 processing in glioblastomas. In contrast, it was shown that mTORC1 plays a role in SREBP-1 processing in cells expressing myr-Akt CAN-10-4108 a short-lived protein with a half-life of about 20 min (45) . Sterol-dependent stabilization of Insig-1 creates a convergent control of SREBP-2 processing for cholesterol homeostasis (45) .
However, we found that Insig-1 expression is not affected by PI3K-mTORC2-Akt-mTORC1 signaling. These results suggest that Insig-1 degradation is not involved in the regulation of SREBP processing by this signaling. PI3K-Akt signaling regulates the ER-to-Golgi transport of SREBP. A recent study showed that Akt phosphorylates SREBP-1 upon insulin stimulation, which in turn promotes its association to coatomer protein (COP) II vesicles and its transport to the Golgi (46) . The association of SREBP-2 with COPII vesicles is not affected by insulin (46) . Results from our current work and others (44) , however suggest a common mechanism that PI3K-Akt-mTORC1 signaling regulates both SREBPs. Whether PI3K-Akt-mTORC1 signaling regulates ER cholesterol level is currently unknown.
In this study, we also investigated a role of PI3K-Akt-mTORC1-SREBP signaling in the integrity of lipid rafts since cholesterol biosynthesis was more promptly regulated by biosynthesis could promptly control lipid rafts on physiological demands. In agreement with this hypothesis, we showed that the inhibition of PI3K-Akt-mTORC1 signaling disrupts lipid rafts. Activation of Akt requires proper lipid raft domains (32) (33) (34) (35) (36) . We also found that the inhibition of SREBP processing or cholesterol biosynthesis suppresses Akt activation in lipid rafts. We thus conclude that the PI3K-Akt-mTORC1-SREBP signaling plays an important role in the maintenance of integrity of lipid rafts (Fig. 6D) . Although the change in lipid raft cholesterol we observed was not as large as that caused by cyclodextrin-mediated cholesterol depletion, a widely used method to disrupt the microdomains, this small change could affect their physiological functions. In addition to cholesterol, other SREBP-regulated products such as isoprenoids and certain fatty acids could play a role in the structure and functions of lipid rafts.
Metabolic reprogramming occurs in many carcinomas. The mTORC1 signaling regulates not only lipogenesis but also glucose metabolism (44) . mTORC1 is activated in malignant human melanomas (50) . Given that GD3 enhances Akt signaling (19, 20) and promotes SREBP pathway, GD3 could be an important factor to induce metabolic reprogramming through PI3K-Akt-mTORC1 signaling independently of oncogenic BRAF signaling in human melanomas.
In conclusion, the current work shows that a positive feedback regulatory loop exists between PI3K-Akt-mTORC1 signaling and SREBP pathway, which boosts Akt signaling in human melanomas expressing GD3.
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